Dapagliflozin is a new and emerging anti-diabetes medication. Dapagliflozin is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, reduces hyperglycemia in patients with type 2 diabetes mellitus (T2DM) by increasing urinary glucose excretion, and weight loss is a consistent associated finding. Because dapagliflozin increases urinary glucose excretion, weight loss could result from reduced body fat secondary to caloric loss or from fluid loss secondary to osmotic diuresis or from a combination of both factors. Nevertheless, whether Dapaglifozin may cause a reduction in visceral fat is unknown.